FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway
出版年份 2019 全文链接
标题
FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway
作者
关键词
-
出版物
JOURNAL OF IMMUNOLOGY
Volume 202, Issue 10, Pages 3065-3075
出版商
The American Association of Immunologists
发表日期
2019-04-13
DOI
10.4049/jimmunol.1801199
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway
- (2017) Ting-ting Wang et al. GUT
- Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
- (2017) Matthew A. Coelho et al. IMMUNITY
- FGF7/FGFR2 signal promotes invasion and migration in human gastric cancer through upregulation of thrombospondin-1
- (2017) Tingting Huang et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
- (2017) Jacob Schachter et al. LANCET
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Tumour CD274 (PD-L1) expression and T cells in colorectal cancer
- (2016) Yohei Masugi et al. GUT
- PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes
- (2016) Matthew W Rosenbaum et al. MODERN PATHOLOGY
- Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer
- (2016) Yaqi Li et al. Molecular Cancer
- Prolongevity hormone FGF21 protects against immune senescence by delaying age-related thymic involution
- (2016) Yun-Hee Youm et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- PD-1/PD-L1 inhibitors
- (2015) Joel Sunshine et al. CURRENT OPINION IN PHARMACOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence
- (2015) Christina Giannopoulou et al. PHARMACOECONOMICS
- Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction
- (2015) Edward P. Carter et al. TRENDS IN CELL BIOLOGY
- Colorectal cancer
- (2015) Ernst J. Kuipers et al. Nature Reviews Disease Primers
- Inhibition of FGFR signaling by PD173074 improves antitumor immunity and impairs breast cancer metastasis
- (2014) Tinghong Ye et al. BREAST CANCER RESEARCH AND TREATMENT
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- The Programmed Death-1 Immune-Suppressive Pathway: Barrier to Antitumor Immunity
- (2014) Suzanne Ostrand-Rosenberg et al. JOURNAL OF IMMUNOLOGY
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer
- (2013) Minmin Song et al. PLoS One
- B7-H1 Expression Is Associated with Poor Prognosis in Colorectal Carcinoma and Regulates the Proliferation and Invasion of HCT116 Colorectal Cancer Cells
- (2013) Sheng-Jia Shi et al. PLoS One
- FGFR2 gene amplification and clinicopathological features in gastric cancer
- (2012) K Matsumoto et al. BRITISH JOURNAL OF CANCER
- Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
- (2012) D. S. Chen et al. CLINICAL CANCER RESEARCH
- Fibroblast Growth Factor Receptor 2 IIIc as a Therapeutic Target for Colorectal Cancer Cells
- (2012) Y. Matsuda et al. MOLECULAR CANCER THERAPEUTICS
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anticancer molecules targeting fibroblast growth factor receptors
- (2012) Guang Liang et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Overexpressed fibroblast growth factor receptor 2 in the invasive front of colorectal cancer: A potential therapeutic target in colorectal cancer
- (2011) Yoko Matsuda et al. CANCER LETTERS
- Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma
- (2010) Ryosuke Hino et al. CANCER
- Signal Transducers and Activators of Transcription-3 Binding to the Fibroblast Growth Factor Receptor Is Activated by Receptor Amplification
- (2010) A. A. Dudka et al. CANCER RESEARCH
- Loss-of-Function Fibroblast Growth Factor Receptor-2 Mutations in Melanoma
- (2009) Michael G. Gartside et al. MOLECULAR CANCER RESEARCH
- De-regulated FGF receptors as therapeutic targets in cancer
- (2009) Victoria Knights et al. PHARMACOLOGY & THERAPEUTICS
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now